Quick Answer
Unicycive Therapeutics, Inc. reported Net Income Loss of -$26.56 million for the year ending 2025.
- Unicycive Therapeutics, Inc. showed an increase of +27.7% in Net Income Loss from 2024 to 2025.
- This data is from Unicycive Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$338.0 thousand | Q3 2020: -$702.0 thousand | Q1 2021: -$964.0 thousand | Q2 2021: -$1.10 million | Q3 2021: -$5.20 million | Q1 2022: -$3.54 million | Q2 2022: -$3.64 million | Q3 2022: -$5.56 million | Q1 2023: -$14.58 million | Q2 2023: -$3.84 million | Q3 2023: -$4.33 million | Q1 2024: -$20.96 million | Q2 2024: $9.86 million | Q3 2024: -$4.10 million | Q1 2025: $570.0 thousand | Q2 2025: -$6.45 million | Q3 2025: -$6.01 million.
- Over the full 6 years of available data (2020 to 2025), Unicycive Therapeutics, Inc.'s Net Income Loss has declined by 1,072.9%.
- Historical annual values: Fiscal year 2025: -$26.56 million | Fiscal year 2024: -$36.73 million | Fiscal year 2023: -$30.54 million | Fiscal year 2022: -$18.06 million | Fiscal year 2021: -$10.02 million | Fiscal year 2020: -$2.26 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: